A Phase 4 interventional study of Oliceridine and Sufentanil in Hypotension and Hypertension, sponsored by Xingguo Xu. Completed at 1 site in China. Open to female participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Xingguo Xu · Phase 4, Interventional, and Prevention
Blood pressure can fall during the start of general anesthesia, particularly in older patients with high blood pressure. This study compared two medicines, oliceridine and sufentanil, to assess their effects on low blood pressure during anesthesia induction in older women with hypertension undergoing gynecological laparoscopic surgery.
This single-center randomized controlled trial enrolled 134 women aged 65 to 80 years at the Affiliated Hospital of Nantong University. Participants were assigned to receive either oliceridine or sufentanil, together with the same other anesthesia induction medicines. Blood pressure and heart rate were measured before induction, one minute after induction, immediately after insertion of the breathing tube, and one and five minutes after insertion.
The main outcome was the proportion of participants who experienced low blood pressure during these measurements. Low blood pressure was defined as a mean arterial pressure below 65 mmHg or a decrease of at least 30% from the value measured before induction. Other assessments included changes and variability in blood pressure, heart rate, and the use of medicines to support blood pressure.
1,021 studies on the registry are indexed under Hypotension; 172 are open to participants now.
This study's enrollment of 134 is above the median of 80 across 686 interventional studies indexed under Hypotension.
Browse Hypotension studies →This is the only study on the registry with Xingguo Xu as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received intravenous oliceridine 0.10 mg/kg during anesthesia induction, together with etomidate 0.15 mg/kg, remimazolam 0.20 mg/kg, and vecuronium 0.10 mg/kg.
Drug: Oliceridine
Participants received intravenous sufentanil 0.50 micrograms/kg during anesthesia induction, together with etomidate 0.15 mg/kg, remimazolam 0.20 mg/kg, and vecuronium 0.10 mg/kg.
Drug: Sufentanil
Intravenous oliceridine 0.10 mg/kg administered during anesthesia induction.
Intravenous sufentanil 0.50 micrograms/kg administered during anesthesia induction.
Incidence of Hypotension During Anesthesia Induction
Percentage of participants with hypotension at any of the four assessment time points: one minute after anesthesia induction, immediately after tracheal intubation, and one and five minutes after intubation. Hypotension is defined as mean arterial pressure (MAP) below 65 mmHg or a decrease of at least 30% from the pre-induction baseline MAP. Participants meeting either criterion at one or more assessment time points are counted once.
Time frame: From one minute after anesthesia induction through five minutes after tracheal intubation.
Minimum Mean Arterial Pressure
Lowest mean arterial pressure (MAP), in mmHg, among measurements obtained one minute after anesthesia induction, immediately after tracheal intubation, and one and five minutes after intubation.
Time frame: From one minute after anesthesia induction through five minutes after tracheal intubation
Maximum Percentage Decrease in Mean Arterial Pressure
Maximum percentage decrease in mean arterial pressure (MAP) from the pre-induction baseline across the four post-induction assessment time points. Percentage decrease is calculated as 100 × (baseline MAP - post-induction MAP) / baseline MAP.
Time frame: From one minute after anesthesia induction through five minutes after tracheal intubation.
Change in Mean Arterial Pressure From Baseline
Change in mean arterial pressure (MAP), in mmHg, from the pre-induction baseline at each assessment time point. Change is calculated as MAP at the assessment time point minus baseline MAP; negative values indicate a decrease.
Time frame: Baseline before induction; one minute after induction; immediately after intubation; one and five minutes after intubation.
Mean Arterial Pressure at Specified Time Points
Mean arterial pressure (MAP), in mmHg, measured before anesthesia induction, one minute after induction, immediately after tracheal intubation, and one and five minutes after intubation.
Time frame: Baseline before induction through five minutes after tracheal intubation.
Heart Rate at Specified Time Points
Heart rate, in beats per minute, measured before anesthesia induction, one minute after induction, immediately after tracheal intubation, and one and five minutes after intubation.
Time frame: Baseline before induction through five minutes after tracheal intubation.
Percentage of Participants Receiving Vasoactive Medication
Percentage of participants receiving at least one vasoactive medication to support blood pressure during the anesthesia induction observation period. Each participant is counted once regardless of the number of doses administered.
Time frame: From initiation of anesthesia induction through five minutes after tracheal intubation.
Plan to share: Undecided — A decision on sharing individual participant data has not yet been made. The study team will review participant consent and institutional requirements before determining whether and how de-identified data can be shared.
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Sep 2026, 4 months.
Of 69 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 76 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oliceridine